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INTRODUCTION
Photodynamic therapy (PDT) utilizes photosen-
sitizing agents that are selectively retained within
tumor cells. The agents remain inactive until exposed
to light of the proper wavelength. When activated by
light, these compounds generate toxic oxygen radicals
that promote tumor necrosis (1). In Japan, PDT has
frequently been used for early lung cancer of the cen-
tral airway (2). In Europe and U.S.A, it has frequently
been used for advanced lung cancer with airway ob-
struction, although Neodymium-doped Yttrium Alu-
minum Garnet (Nd-YAG) laser is used for this pro-
cedure in Japan (3, 4). Recently, several reports dem-
onstrated that bronchial disobliteration achieved
with PDT is equally good but has a longer lasting
effect compared to that with Nd-YAG laser (5, 6).
And it can safely be applied to obstructive tumors.
In this paper, we performed PDT for a glandular
type of adenocarcinoma of the central bronchuswhich
showed submucosal growth in the bronchus. PDT
was very effective for this tumor.
CASE REPORT
A 75-year-old man was referred to our hospital be-
cause of the emphysema and tumor of the right in-
termediate bronchus. He was diagnosed as having
emphysema at 72 years old, and was receiving home
oxygen therapy at the time of referral. Brinkman index
was 1500 (30 cigarettes/day×50 years). On admis-
sion, he was experiencing severe dyspnea. Chest x-ray
film demonstrated radiolucency of the bilateral lung
fields and lower diaphragm, which are findings specific
to emphysema. Thoracic CT scan demonstrated a ho-
mogenous tumor of the right intermediate bronchus
and the maximal size of the tumorwas 1.3 cm (Figure
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1-a). There were no elevated tumor markers (SCC,
syfra, CEA,NSE, proGRP). Bronchoscopic examination
demonstrated a spherical tumor of the right interme-
diate bronchus covered by normal mucosa (Figure
1-b). The biopsy specimen obtained from this tumor
was histologically diagnosed as“glandular type of ade-
nocarcinoma of the bronchus”(Figure 1-c). The pa-
tient was staged as clinical T1N0M0, stage IA. On
pulmonary function test, Vital Capacity was 2100 ml
(63%) and Forced Expiratory Volume 1.0 was 730 ml
(40%). The blood gaswas pH 7.394, PaCO2 41.7mmHg,
and PaO2 80.4 mmHg. Since surgical treatment was
not feasible because of poor pulmonary function, we
selected photodynamic therapy (PDT). The patient
was informed about“PDT for the advanced lung cancer
with endoluminal obstructive lesions of the airway”
and signed consent.
Photosensitizer, porfimer sodium (Photofrin) was
intravenously administered at a dose of 2mg/kg body
weight. After an interval of 48 h bronchoscopic illu-
mination of the tumour was carried out using an ex-
cimer dye laser. The amount of illumination was 100
J using a terminal lens diffuser and 200 J using a ter-
minal cylindrical diffuser. After 2 weeks and again after
1 month of illumination, bronchoscopic examination
showed a necrotic tumor coated with black debris
(Figure 2-a, b). After 4 months the tumor disappeared
(Figure 2-c). The biopsy obtained from the lesion
site demonstrated“no malignancy”.
Bronchoscopic examination 9 months after PDT
found a polypoid tumor arising from the right B6
bronchus, which was diagnosed as squamous cell
carcinoma by biopsy. However, tumor of the right
intermediate bronchus did not recur. For lung cancer
in B6 bronchus, we periodically performed several
sessions of Nd-YAG laser therapy, PDT and radiother-
apy with 60 Gy over the subsequent 2 years 6months.
The patient died of respiratory failure due to the tumor
of B6 bronchus. However, there was no recurrence
of the tumor of the right intermediate bronchus for
Figure 1
a)Thoracic CT scan demonstrated a homogenous tumor
(arrow) of the right intermediate bronchus.
b)Bronchoscopic examination demonstrated a spherical
tumor of the right intermediate bronchus covering a
normal mucosa.
c)The biopsy specimen obtained from this tumor was
histologically diagnosed as“glandular type of adeno-
carcinoma of the bronchus”
The Journal of Medical Investigation Vol. 52 August 2005 ２０９
ａ ｂ
ｃ
3 years 3 months.
DISCUSSION
In lung cancer, PDT can be applied as a curative
therapy for early cancer of the trachea and central
bronchi and as a palliative therapy for treatment of
nonresectable disease with endobronchial obstruction
(6). It is very rare for submucosal tumor of the bron-
chus to be treated using PDT.We presented a patient
with submucosal tumor of the right intermediate
bronchus, who was considered a candidate for bron-
choplasty. As he had severe emphysema (FEV1.0
730 ml (40%)), we selected PDT as a palliative therapy.
This tumor did not meet for the criteria for early lung
cancer of the central airway proposed by the JapanLung
Cancer Society (7). The tumorwas not squamous cell
carcinoma, and was suspected of invading through
the bronchial wall to the lung parenchyma. However,
PDT for this tumor was very effective, and the tumor
showed complete response for about 3 years.
In recent years, some patients with substantial en-
doluminal obstructive lesions of the airway have
been treated by endobronchial therapies, such as
PDT, electrocautery, Nd-YAG laser, cryotherapy, or
endobronchial brachytherapy (8). In Japan, PDT is
frequently used for early lung cancer of the central
airway (2). In Europe and the U.S.A, this procedure
is frequently used for advanced lung cancer with airway
obstruction (3, 4). Moghissi reviewed 24 articles de-
scribing PDT for lung cancer (9). Cases included 636
advanced lung cancers and 517 early lung cancers.
In the patients with advanced lung cancer, there was
no procedure-related mortality and almost all patients
had symptomatic relief, indicating that PDT is effective
for palliation of inoperable advanced lung cancer.
Moghissi et al. also concluded that endoscopic PDT
for patients with advanced lung cancer causingmajor
airway obstruction ismore effective thanNd-YAG laser
Figure 2
a)Two weeks after PDT. Bronchoscopic examination
showed necrotic tumor coated the black debris.
b)One month after PDT. The size of the necrotic tumor
coated the black debris decreased.
c)Four months after PDT, the tumor was disappeared.
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treatment with respect to percent of luminal patency
and pulmonary functions at 1 month, and that it may
be superior in terms of duration of response (5). Futher-
more, it may be applied safely to small segmental (and
even subsegmental) tumors (10). Nd-YAG laser is
contraindicated in patients with submucosal lesions
because of the potential for perforation of a bronchus
or major vessel. However, PDT can be applied to these
lesions safely, shown by the case presented in this
paper.
Moreover, Moghissi et al. reported combined ther-
apy using Nd-YAG laser and endoscopic photody-
namic therapy, which is an effective palliative treatment
for patients with inoperable endotracheobronchial
cancer (10). Initially patients underwent broncho-
scopic Nd-YAG laser treatment to debulk the tumor,
followed six weeks later by photodynamic therapy
to treat the residual tumor. PDT often needs to be
used in conjunction with other techniques, such as
airway stenting, Nd-YAG, or cryotherapy. For PDT to
be used effectively, it should be integrated into a
multimodal approach with chemotherapy and ra-
diation (11). The optimal sequencing of these treat-
ment modalities remains an area for further inves-
tigation.
In conclusion, PDT can affect a submucosal tumor
or small airway tumor, as well as various other tumors
causing airway obstruction. Patients with inoperable
malignant and tracheobronchial obstruction (irre-
spective of the histological type), may well benefit
from the expanding the application of PDT.Our report
recommends that PDT should be applied not only
to early lung cancer but also to submucosal tumor of
the central bronchus.
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